Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 18 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 5 institutions in 3 countries.
Florian BleffertInstitute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich GmbH, Jülich, Germany.
Joachim GranzinInstitute of Biological Information Processing - Structural Biochemistry (IBI-7: Structural Biochemistry), Forschungszentrum Jülich GmbH, Jülich, Germany.
Muttalip CaliskanInstitute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich GmbH, Jülich, Germany.
Stephan N Schott-VerdugoInstitute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Duesseldorf, Germany.
Meike SiebersInstitute of Molecular Physiology, and Biotechnology of Plants (IMBIO), University of Bonn, Bonn, Germany.
Björn ThieleInstitute of Bio- and Geosciences, Plant Sciences (IBG-2), and Agrosphere (IBG-3), Forschungszentrum Jülich GmbH, Jülich, Germany.
Laurence RahmeDepartment of Microbiology, and Immunobiology, Harvard Medical School, Boston, United States.ORCID 0000-0002-5374-4332
Sebastian FelgnerDepartment of Molecular Bacteriology, Helmholtz Centre for Infection Research, Braunschweig, Germany.ORCID 0000-0003-0030-2490
Peter DörmannInstitute of Molecular Physiology, and Biotechnology of Plants (IMBIO), University of Bonn, Bonn, Germany.ORCID 0000-0002-5845-9370
Holger GohlkeInstitute of Biological Information Processing - Structural Biochemistry (IBI-7: Structural Biochemistry), Forschungszentrum Jülich GmbH, Jülich, Germany.ORCID 0000-0001-8613-1447
Renu Batra-SafferlingInstitute of Biological Information Processing - Structural Biochemistry (IBI-7: Structural Biochemistry), Forschungszentrum Jülich GmbH, Jülich, Germany.ORCID 0000-0002-8597-4335
Karl-Erich JaegerInstitute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich GmbH, Jülich, Germany.
Filip KovacicInstitute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich GmbH, Jülich, Germany.ORCID 0000-0002-0313-427X
Forschungszentrum Jülich · DEUniversity of Bonn · DEHarvard University · USHelmholtz Centre for Infection Research · DEUniversity of Talca · CL
Funding
A comprehensive investigation of Pseudomonas quorum sensing regulatory relationships and the consequences on quorum sensing inhibitors in complex communitiesR01AI177555 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LAURENCE G RAHME · 2023 to 2026
$3.4M
NIAID NIH HHS R01 AI177555
6 · The paper itself
Abstract
Cells steadily adapt their membrane glycerophospholipid (GPL) composition to changing environmental and developmental conditions. While the regulation of membrane homeostasis via GPL synthesis in bacteria has been studied in detail, the mechanisms underlying the controlled degradation of endogenous GPLs remain unknown. Thus far, the function of intracellular phospholipases A (PLAs) in GPL remodeling (Lands cycle) in bacteria is not clearly established. Here, we identified the first cytoplasmic membrane-bound phospholipase A
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Structural, mechanistic, and physiological insights into phospholipase A-mediated membrane phospholipid degradation in · full record | OpenQuestion